|
1) Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol. 2004; 22: 330
|
|
|
|
2) Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002; 20: 1335-43
|
|
|
|
|
3) Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001; 19: 1336-43
|
|
|
|
|
|
4) von Plessen C, Bergman B, Andresen O, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer. 2006; 95: 966-73
|
|
|
|
|
|
5) Park JO, Kim SW, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are ninprogressive after two cycles of platinum-based chemotherapy in nin small-cell lung cancer. J Clin Oncol. 2007; 25: 5233
|
|
|
|
|
|
6) Barata FJ, Parente B, Teixeira EÃo, et al. Optimal duration of chemotherapy in non-small-cell lung cancer: multicenter, randomized, prospective clinical trial comparing 4 vs 6 cycles of carboplatin and gemcitabine: P2-235. J Thorac Oncol. 2007; 2: S666
|
|
|
|
|
|
7) Soon Y, Stockler MR, Boyer M, et al. Duration of chemotherapy for advanced non-small cell lung cancer; an update systemic review and meta-analysis. J Clin Oncol(Meeting Abstracts). 2008; 26: 8013
|
|
|
|
|
|
8) Westeel V, Quoix E, Moro-Sibilot D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2005; 97: 499-506
|
|
|
|
|
|
9) Brodowicz T, Krakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase II trial. Lung Cancer. 2006; 52: 155-63
|
|
|
|
|
|
10) Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 2003; 21: 2933-9
|
|
|
|
|
|
11) Belani CP, Perry MC, La Rocca RV, et al. Maintenance therapy with weekly paclitaxel improves outcome for advanced non-small cell lung cancer patients. Proc Am Soc Clin Oncol. 2005; 23: 656s
|
|
|
|
|
|
12) Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27: 591-8
|
|
|
|
|
|
13) Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009; 374: 1432-40
|
|
|
|
|
|
14) Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol. 2009; 27: 15s (suppl; abstr 8001)
|
|
|
|
|
|
15) Miller VA, O'Connor P, Soh C, et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2009; 27: 18s (suppl; abstr LBA8002)
|
|
|
|
|